Cargando…

Do prokinetic agents provide symptom relief through acceleration of gastric emptying? An update and revision of the existing evidence

BACKGROUND: Gastroparesis and functional dyspepsia are disorders characterized by upper gastrointestinal symptoms and multifaceted etiologies. One of the main therapeutic approaches is accelerating gastric emptying (GE) by means of prokinetic agents. Their efficacy has been demonstrated, although th...

Descripción completa

Detalles Bibliográficos
Autores principales: Goelen, Nick, Jones, Mike, Huang, I‐Hsuan, Carbone, Florenca, Janssen, Pieter, Tack, Jan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10039797/
https://www.ncbi.nlm.nih.gov/pubmed/36714973
http://dx.doi.org/10.1002/ueg2.12362
_version_ 1784912345405849600
author Goelen, Nick
Jones, Mike
Huang, I‐Hsuan
Carbone, Florenca
Janssen, Pieter
Tack, Jan
author_facet Goelen, Nick
Jones, Mike
Huang, I‐Hsuan
Carbone, Florenca
Janssen, Pieter
Tack, Jan
author_sort Goelen, Nick
collection PubMed
description BACKGROUND: Gastroparesis and functional dyspepsia are disorders characterized by upper gastrointestinal symptoms and multifaceted etiologies. One of the main therapeutic approaches is accelerating gastric emptying (GE) by means of prokinetic agents. Their efficacy has been demonstrated, although the association between symptom improvement and acceleration of emptying is less clear. Meta‐analyses have found contradictory results. Differences in applied methodology and included trials might drive these contradictions. OBJECTIVE: To provide a transparent meta‐analysis update to elucidate the association between symptom improvement and acceleration of GE due to gastroprokinetic agents available for long‐term use in patients with gastroparesis. DESIGN: Two approaches from earlier meta‐analyses were executed and compared. One analyzed the relative changes on active treatment versus baseline, the other compared the change from baseline on active treatment versus the change from baseline on placebo. Papers that reported sufficient numerical data for both analyses were selected. Both analyses included the same trials. RESULTS: Overall, both approaches yield the same positive direction of association between symptom improvement and acceleration of emptying (0.291 (−0.391, 0.972), p = 0.4 and 0.453 (0.123, 0.782), p = 0.007 for the active‐only and placebo‐controlled analysis respectively). The association between symptom improvement and GE acceleration for studies using optimal GE tests was either 0.028 (p > 0.9) or 0.463 (p = 0.007), and for sub‐optimal GE tests was either 0.370 (p = 0.4) or 0.052 (p > 0.9) depending on the used meta‐analysis methodology. CONCLUSIONS: The applied methodology for GE testing, and the meta‐analysis substantially impacts the conclusion. When considering the clinically relevant outcome of improvement from baseline, symptoms and emptying improve with prokinetics, but no correlation is found between both aspects. When the change over placebo is considered, limiting the analysis to scientifically more rigorous study approaches, changes in emptying rate and symptom improvement are positively associated.
format Online
Article
Text
id pubmed-10039797
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-100397972023-03-26 Do prokinetic agents provide symptom relief through acceleration of gastric emptying? An update and revision of the existing evidence Goelen, Nick Jones, Mike Huang, I‐Hsuan Carbone, Florenca Janssen, Pieter Tack, Jan United European Gastroenterol J Neurogastroenterology BACKGROUND: Gastroparesis and functional dyspepsia are disorders characterized by upper gastrointestinal symptoms and multifaceted etiologies. One of the main therapeutic approaches is accelerating gastric emptying (GE) by means of prokinetic agents. Their efficacy has been demonstrated, although the association between symptom improvement and acceleration of emptying is less clear. Meta‐analyses have found contradictory results. Differences in applied methodology and included trials might drive these contradictions. OBJECTIVE: To provide a transparent meta‐analysis update to elucidate the association between symptom improvement and acceleration of GE due to gastroprokinetic agents available for long‐term use in patients with gastroparesis. DESIGN: Two approaches from earlier meta‐analyses were executed and compared. One analyzed the relative changes on active treatment versus baseline, the other compared the change from baseline on active treatment versus the change from baseline on placebo. Papers that reported sufficient numerical data for both analyses were selected. Both analyses included the same trials. RESULTS: Overall, both approaches yield the same positive direction of association between symptom improvement and acceleration of emptying (0.291 (−0.391, 0.972), p = 0.4 and 0.453 (0.123, 0.782), p = 0.007 for the active‐only and placebo‐controlled analysis respectively). The association between symptom improvement and GE acceleration for studies using optimal GE tests was either 0.028 (p > 0.9) or 0.463 (p = 0.007), and for sub‐optimal GE tests was either 0.370 (p = 0.4) or 0.052 (p > 0.9) depending on the used meta‐analysis methodology. CONCLUSIONS: The applied methodology for GE testing, and the meta‐analysis substantially impacts the conclusion. When considering the clinically relevant outcome of improvement from baseline, symptoms and emptying improve with prokinetics, but no correlation is found between both aspects. When the change over placebo is considered, limiting the analysis to scientifically more rigorous study approaches, changes in emptying rate and symptom improvement are positively associated. John Wiley and Sons Inc. 2023-01-30 /pmc/articles/PMC10039797/ /pubmed/36714973 http://dx.doi.org/10.1002/ueg2.12362 Text en © 2023 The Authors. United European Gastroenterology Journal published by Wiley Periodicals LLC on behalf of United European Gastroenterology. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ (https://creativecommons.org/licenses/by-nc-nd/4.0/) License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made.
spellingShingle Neurogastroenterology
Goelen, Nick
Jones, Mike
Huang, I‐Hsuan
Carbone, Florenca
Janssen, Pieter
Tack, Jan
Do prokinetic agents provide symptom relief through acceleration of gastric emptying? An update and revision of the existing evidence
title Do prokinetic agents provide symptom relief through acceleration of gastric emptying? An update and revision of the existing evidence
title_full Do prokinetic agents provide symptom relief through acceleration of gastric emptying? An update and revision of the existing evidence
title_fullStr Do prokinetic agents provide symptom relief through acceleration of gastric emptying? An update and revision of the existing evidence
title_full_unstemmed Do prokinetic agents provide symptom relief through acceleration of gastric emptying? An update and revision of the existing evidence
title_short Do prokinetic agents provide symptom relief through acceleration of gastric emptying? An update and revision of the existing evidence
title_sort do prokinetic agents provide symptom relief through acceleration of gastric emptying? an update and revision of the existing evidence
topic Neurogastroenterology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10039797/
https://www.ncbi.nlm.nih.gov/pubmed/36714973
http://dx.doi.org/10.1002/ueg2.12362
work_keys_str_mv AT goelennick doprokineticagentsprovidesymptomreliefthroughaccelerationofgastricemptyinganupdateandrevisionoftheexistingevidence
AT jonesmike doprokineticagentsprovidesymptomreliefthroughaccelerationofgastricemptyinganupdateandrevisionoftheexistingevidence
AT huangihsuan doprokineticagentsprovidesymptomreliefthroughaccelerationofgastricemptyinganupdateandrevisionoftheexistingevidence
AT carboneflorenca doprokineticagentsprovidesymptomreliefthroughaccelerationofgastricemptyinganupdateandrevisionoftheexistingevidence
AT janssenpieter doprokineticagentsprovidesymptomreliefthroughaccelerationofgastricemptyinganupdateandrevisionoftheexistingevidence
AT tackjan doprokineticagentsprovidesymptomreliefthroughaccelerationofgastricemptyinganupdateandrevisionoftheexistingevidence